Informações de Arvinas Inc

Mais detalhes de Arvinas Inc Empresa

Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393 and ARV-102. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.



Código da empresaARVN

Nome da EmpresaArvinas Inc

Data de listagemSep 27, 2018

CEODr. John G. Houston, Ph.D.

Número de funcionários430

Tipo de títulosOrdinary Share

Fim do ano fiscalSep 27

Endereço5 Science Park

CidadeNEW HAVEN

Bolsa de valoresNASDAQ Global Select Consolidated

PaísUnited States of America

Código postal06511-1966

Telefone12035351456

Sitehttps://www.arvinas.com/

Código da empresaARVN

Data de listagemSep 27, 2018

CEODr. John G. Houston, Ph.D.

Executivos da empresa Arvinas Inc



Nome

Nome/Posição

Posição

Ações detidas

Variação

Dr. John G. Houston, Ph.D.

Chairman of the Board, President, Chief Executive Officer

912.27K

-7.52%

Dr. Angela Cacace, Ph.D.

Chief Scientific Officer

74.86K

-3.34%

Dr. Noah Berkowitz, M.D., Ph.D.

Chief Medical Officer

66.81K

+827.20%

Ms. Leslie V. Norwalk, Esq.

Independent Director

26.05K

+159.93%

Mr. Everett V. Cunningham

Independent Director

26.05K

+159.93%

Dr. Sunil Agarwal, M.D.

Independent Director

24.67K

+185.35%

Mr. Edward (Ted) Kennedy, Jr.

Independent Director

--

Dr. Laurie Smaldone Alsup, M.D.

Independent Director

--

Mr. Briggs W. Morrison, M.D.

Lead Independent Director

--

Mr. Andrew Saik

Chief Financial Officer, Treasurer

--

Ver Mais

Nome

Nome/Posição

Posição

Ações detidas

Variação

Dr. John G. Houston, Ph.D.

Chairman of the Board, President, Chief Executive Officer

912.27K

-7.52%

Dr. Angela Cacace, Ph.D.

Chief Scientific Officer

74.86K

-3.34%

Dr. Noah Berkowitz, M.D., Ph.D.

Chief Medical Officer

66.81K

+827.20%

Ms. Leslie V. Norwalk, Esq.

Independent Director

26.05K

+159.93%

Mr. Everett V. Cunningham

Independent Director

26.05K

+159.93%

Dr. Sunil Agarwal, M.D.

Independent Director

24.67K

+185.35%

Detalhamento da receita

FY2025Q2

FY2025Q1

FY2024

FY2023

Sem dados

Por RegiãoUSD

Nome

Receita

Proporção

United States

22.40M

0.00%

Por Empresa

Por Região

Sem dados

Distribuição de ações

Atualizado em: sáb, 16 de ago

Investidores

Tipos de investidores

Investidores

Proporção

The Vanguard Group, Inc.

13.31%

BlackRock Institutional Trust Company, N.A.

8.19%

Citadel Advisors LLC

5.72%

Pfizer Inc

5.38%

Logos Global Management LP

3.89%

Outro

63.50%

Investidores

Proporção

The Vanguard Group, Inc.

13.31%

BlackRock Institutional Trust Company, N.A.

8.19%

Citadel Advisors LLC

5.72%

Pfizer Inc

5.38%

Logos Global Management LP

3.89%

Outro

63.50%

Tipos de investidores

Investidores

Proporção

Investment Advisor

40.00%

Hedge Fund

31.67%

Investment Advisor/Hedge Fund

20.33%

Venture Capital

6.47%

Corporation

5.38%

Research Firm

4.69%

Individual Investor

2.59%

Pension Fund

0.62%

Bank and Trust

0.29%

Participação acionária institucional



Atualizado em: qua, 1 de out

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q3

512

68.52M

105.75%

-25.73M

2025Q2

507

73.45M

100.08%

-16.70M

2025Q1

525

68.48M

93.89%

-22.67M

2024Q4

505

80.31M

116.78%

-4.24M

2024Q3

496

79.95M

116.50%

-140.10K

2024Q2

489

78.26M

114.11%

+1.71M

2024Q1

494

75.44M

110.48%

+3.48M

2023Q4

497

68.16M

100.81%

+12.55M

2023Q3

472

52.04M

94.71%

-3.94M

2023Q2

473

53.77M

100.76%

-3.55M

Ver Mais

Atividade dos acionistas



Nome

Ações detidas

Proporção

Variação

Var. %

Data

The Vanguard Group, Inc.

9.38M

12.78%

+1.03M

+12.34%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

5.26M

7.16%

+221.27K

+4.39%

Jun 30, 2025

Citadel Advisors LLC

3.67M

5%

-201.53K

-5.20%

Jun 30, 2025

Pfizer Inc

3.46M

4.71%

--

Jun 30, 2025

Logos Global Management LP

4.80M

6.54%

+1.50M

+45.45%

Aug 18, 2025

D. E. Shaw & Co., L.P.

2.15M

2.93%

+2.15M

--

Jun 30, 2025

Millennium Management LLC

1.90M

2.59%

+587.75K

+44.85%

Jun 30, 2025

State Street Investment Management (US)

1.73M

2.36%

-163.87K

-8.64%

Jun 30, 2025

Opaleye Management Inc.

1.68M

2.29%

-295.00K

-14.94%

Jun 30, 2025

New Leaf Venture Partners LLC

1.59M

2.16%

--

Jun 30, 2025

Ver Mais

ETFs Relacionados



Atualizado em: qui, 6 de nov

Nome

Proporção

SPDR S&P Pharmaceuticals ETF

1.28%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

0.96%

Virtus LifeSci Biotech Clinical Trials ETF

0.81%

Invesco NASDAQ Future Gen 200 ETF

0.53%

Federated Hermes MDT Small Cap Core ETF

0.26%

iShares U.S. Pharmaceuticals ETF

0.23%

Zacks Small/Mid Cap ETF

0.19%

First Trust Small Cap Growth AlphaDEX Fund

0.13%

iShares Health Innovation Active ETF

0.1%

Invesco Nasdaq Biotechnology ETF

0.07%

Ver Mais

SPDR S&P Pharmaceuticals ETF

Proporção1.28%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

Proporção0.96%

Virtus LifeSci Biotech Clinical Trials ETF

Proporção0.81%

Invesco NASDAQ Future Gen 200 ETF

Proporção0.53%

Federated Hermes MDT Small Cap Core ETF

Proporção0.26%

iShares U.S. Pharmaceuticals ETF

Proporção0.23%

Zacks Small/Mid Cap ETF

Proporção0.19%

First Trust Small Cap Growth AlphaDEX Fund

Proporção0.13%

iShares Health Innovation Active ETF

Proporção0.1%

Invesco Nasdaq Biotechnology ETF

Proporção0.07%

Dividendo



Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Sem dados

Desdobramento de ações



Data

Tipo

Proporção

Sem dados

Data

Tipo

Proporção

Sem dados